Kyntra BIO vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $6.4m for Kyntra BIO (3.9 times as much). Kyntra BIO grew faster (-78.3% against -87.9%). Kyntra BIO kept more of each dollar of sales as profit: a net margin of 2848.6% against -565.5%.
| Latest fiscal year | Kyntra BIOKYNB, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $6.4m | $25.4m |
| Revenue growth | -78.3% | -87.9% |
| Net income | $183m | −$144m |
| Operating margin | -712.7% | -621.1% |
| Net margin | 2848.6% | -565.5% |
| Return on equity | — | -39.1% |
| Free cash flow | −$4.8m | −$130m |
| Cash | $47.9m | $90.4m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 34 | 152 |
| Market value | $17.5m | $185m |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | — |
| Insider trades, 12 months | 4 buys, 0 sales | 17 buys, 44 sales |